|Day's Range||80.57 - 81.02|
|52 Week Range||66.93 - 83.58|
|PE Ratio (TTM)||28.80|
|Dividend & Yield||2.72 (3.37%)|
|1y Target Est||N/A|
As Novartis considers asset sales that could raise $50 billion, investors are worried any cash raised may give the Swiss drugmaker firepower for another unsuccessful megadeal. Novartis's $52 billion takeover of U.S.-based eye care giant Alcon, completed in 2011, saddled it with a business whose sales and profit have faltered two years running. Now, Chief Executive Joe Jimenez is reviewing Alcon's surgical devices and contact lens businesses, suggesting they could be valued at $25-$35 billion if he unloads them.
Why Pfizer, Novartis, and Sanofi rank at the top of all dividend stocks in the generic-drug industry.
A costly learning exercise.